|
| | RVX-208 Basic information |
| Product Name: | RVX-208 | | Synonyms: | 2-(4-(2-hydroxyethoxy)-3,5-diMethylphenyl)-5,7-diMethoxyquinazolin-4(3H)-one;RVX-000222;4(3H)-Quinazolinone, 2-[4-(2-hydroxyethoxy)-3,5-dimethylphenyl]-5,7-dimethoxy-;2-[4-(2-hydroxyethoxy)-3,5-dimethylphenyl]-5,7-dimethoxy-4(3H)-quinazolinone RVX-208;RVX-208;Apabetalone;Apabetalone-RVX-208;RVX-208(RVX 000222) | | CAS: | 1044870-39-4 | | MF: | C20H22N2O5 | | MW: | 370.4 | | EINECS: | | | Product Categories: | Inhibitors | | Mol File: | 1044870-39-4.mol |  |
| | RVX-208 Chemical Properties |
| Boiling point | 594.2±60.0 °C(Predicted) | | density | 1.28±0.1 g/cm3(Predicted) | | storage temp. | -20°C (des.) | | solubility | Soluble in DMSO (up to 75 mg/ml) or in Ethanol (up to 4 mg/ml). | | form | solid | | pka | 14.21±0.10(Predicted) | | color | White | | Stability: | Stable for 2 years from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20° for up to 1 month. |
| | RVX-208 Usage And Synthesis |
| Description | The bromodomain and extra terminal (BET) proteins interact with acetylated lysine-containing sequences on target proteins via their bromodomains, commonly altering gene transcription. The human BET proteins contain two bromodomains, the first (BD1) being closer to the N-terminus than the second (BD2). RVX-208 is a selective antagonist of BET bromodomains, binding with 10-100-fold higher affinity for BD2 (IC50 = 0.04-0.28 μM) over BD1 (IC50 = 1.8-3.1 μM). RVX-208 causes the selective release of BET proteins from chromatin in cells. It interferes with the BET protein BRD4, resulting in an increased expression of apolipoprotein (Apo) A1 in cells, mice, monkeys, and humans. RVX-208 also reduces atherosclerosis in hyperlipidemic ApoE-deficient mice. | | Uses | RVX-208 is a selective antagonist of bromodomain and extra terminal (BET)’s bromodomains. | | target | BD2 | | References | 1) Picaud?et al. (2013),?RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain; Proc. Natl. Acad. Sci. USA,?110?19754
2) McLure?et al. (2013),?RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonist; PLoS One,?8e83190
3) Bailey?et al. (2010),?RVX-208: a small molecule that increases apolipoprotein A-I and high-density lipoprotein cholesterol in vitro and in vivo; J. Am. Coll. Cardiol.,?55?2580
4) Jahagirdar?et al. (2014),?A novel BET bromodomain inhibitor, RVX-208 shows reduction of atherosclerosis in hyperlipidemic ApoE deficient mice; Atherosclerosis,?236?91 |
| | RVX-208 Preparation Products And Raw materials |
| Raw materials | Benzamide, 2-bromo-4,6-dimethoxy--->Benzonitrile, 2-amino-4,6-dimethoxy--->2-(4-HYDROXY-3,5-DIMETHYLPHENYL)-5,7-DIMETHOXYQUINAZOLIN-4(3H)-ONE-->3,5-diMethoxyaniline hydrochloride-->3,5-Dimethyl-4-hydroxybenzaldehyde-->2-Bromo-4,6-dimethoxybenzoic acid-->4-(2-hydroxyethoxy)-3,5-dimethylbenzaldehyde-->2-aMino-4,6-diMethoxybenzaMide-->C17H28O3Si-->4,6-DIMETHOXY-1H-INDOLE-2,3-DIONE-->2-AMINO-4,6-DIMETHOXY-BENZOIC ACID-->1-Bromo-3,5-dimethoxybenzene-->3,5-Dimethoxybenzoic acid-->3,5-Dihydroxybenzoic acid-->3,5-Dimethoxyaniline |
|
